 Regenxbio Inc NASDAQ: RGNX is trading significantly higher Monday after the company, and AbbVie Inc NYSE: ABBV, announced an eye care collaboration. The companies will develop and commercialize RGX-314, an investigational gene therapy for wet age-related macular degeneration, diabetic retinopathy and other chronic retinal diseases. 